Bonum Therapeutics

Heading to Breckenridge for Keystone Symposia’s “Antibodies as Drugs: The Art in Antibody Engineering” conference, May 5-8? Don’t miss your chance to learn about Bonum’s technology to generate conditionally activated protein therapeutics, and our lead asset, cLAG3-IL2. ✅ Talk: “A novel method for generating regulated cytokine therapeutics: Safety and activity of a conditionally active cLAG3-IL2 in a simple antibody format” Presenter: John Mulligan, Ph.D. Date: May 7 | 8-11 am MT ✅ Poster #1: “Development of a new class of targeted and conditional cytokine therapeutics using a novel dual-binding antibody-based platform” ✅ Poster #2: “A novel method for generating regulated cytokine therapeutics: Safety and activity of a conditionally active cLAG3-IL2 in a simple antibody format” For more information, read the full release: https://ow.ly/9xZw50RqT0V #ksantibodyeng24 Keystone Symposia on Molecular & Cellular Biology

Inspiring science? Check ✅ Fueling progress? Check ✅ Revolutionizing care? Check ✅ Bonum team members Justin Killebrew, Ph.D., Diane Hollenbaugh, Ph.D., Shannon Okada, and John Mulligan, Ph.D. enjoyed sharing data on our lead candidate, cLAG3-IL2, and learning about the latest advances in cancer science and medicine at #AACR24! Thanks to the American Association for Cancer Research for hosting yet another informative annual meeting. Next Up: #KSAntibodyEng24 in Breckenridge, CO, May 5-8, 2024

We were delighted to present our poster at #AACR24 this morning! Missed us? Take a closer look at the preclinical data on our lead program, cLag3-IL2, demonstrating the power of Bonum's technology platform: https://ow.ly/UQ1e50RbTEo

Heading to #AACR24? Connect with John Mulligan, Ph.D., Diane Hollenbaugh, Ph.D., Justin Killebrew, Ph.D., & Shannon Okada as they share preclinical data for the first time on our lead program, cLag3-IL2, demonstrating the power of Bonum’s technology platform. Don’t miss Bonum's poster on our conditionally active therapeutic that targets IL-2 to LAG3+ cells while remaining systemically inert, even at high treatment doses. Abstract Number: 4062 Date/Time: Tuesday, April 9, 2024 - 9:00 AM - 12:30 PM Session Title: Immune Modulation with Cytokines For more information: https://ow.ly/ZkQA50R7Xme

Systemic Delivery, Local Activity: Bonum is focused on a proven technology that utilizes regulation to create targeted, highly active, and less toxic medicines. Connect with John Mulligan, Ph.D., Diane Hollenbaugh, Ph.D., Justin Killebrew, Ph.D., & Shannon Okada at #AACR24 as they share preclinical data on our lead program, cLAG3-IL2.

Meeting investors', buyers', and sellers' goals isn't easy. Bonum's Chief Business Officer Neela Patel offers advice on how to negotiate a winning deal that leaves all parties positioned for success. Check out her insights in the Spring 2024 Issue of Drug Discovery World, starting on page 62: https://lnkd.in/gjdARyER

Heading to #AACR24? Don't miss the Bonum team presenting pre-clinical data on our lead program, cLAG3-IL2. For background on our powerful technology platform and the therapeutic potential of cytokines, check out The Bio Report podcast with Bonum's Diane Hollenbaugh and Neela Patel. Listen now: https://ow.ly/FruH50QVUzI Levine Media Group Daniel Levine

TODAY: Don't miss Bonum's CBO Neela Patel at the Fierce BD&L Summit for Life Sciences 2024 as part of the “Creative Deal Structures for Traditional Asset Based Deals" panel discussion from 1:15-2:00pm PDT. For more info: https://www.bdlsummit.com/ #FierceBiotech #FiercePharma

Bonum's Chief Business Officer Neela Patel will be at the Fierce BD&L Summit for Life Sciences 2024 as part of the “Creative Deal Structures for Traditional Asset Based Deals" panel from 1:15-2:00pm PDT on Monday, March 11. More information and registration here: https://lnkd.in/exeAQZJy #FierceBiotech #FiercePharma Fierce Life Sciences Events

We are excited to be sharing preclinical data for the first time at #AACR24 on our lead program, cLAG3-IL2, demonstrating the power of Bonum's technology platform. Don't miss our poster on Bonum's conditionally active therapeutic that targets IL-2 to LAG3+ cells while remaining systemically inert, even at high treatment doses. Abstract Number: 4062 Date/Time: Tuesday, April 9, 2024 - 9:00 AM - 12:30 PM Session Title: Immune Modulation with Cytokines For more information: https://lnkd.in/gZR8u4_w